New OPEX Facility in Germany Showcases Next Generation Automation Solutions to Benefit Customers Worldwide
9.11.2021 17:30:00 EET | Business Wire | Press release
OPEX Corporation, a global provider of innovative warehouse, document and mail automation solutions, is opening a new facility in Germany where customers and product resellers may learn about, test and interact with OPEX automation technology that improves workflow, accelerates change, and drives efficiencies in infrastructure.
Located in the northern German city of Duisburg, the new facility will offer convenient, in-person access to European and international travel, and will be outfitted with remote capabilities when travel is not possible.
The newly leased facility, which will be fully operational in early 2022, will be the only European hub for demonstrating the full range of OPEX solutions to both direct customers and OPEX’s extensive network of product resellers. Currently, the only other facility of its kind is OPEX’s world headquarters in New Jersey.
“Most of our solutions are built to order, so it is important that customers be able to learn about and interact with the technology to better understand how it benefits their business,” said Shaun Lee, OPEX Director of Operations for Europe, Middle East and Africa (EMEA). “We work with clients to simulate the customer’s actual environment and needs to provide an in-depth, end-to-end demonstration of our solutions in action.”
Other features of the new German facility include:
- Training classes to help customers, resellers and OPEX employees learn warehouse, document and mail automation capabilities and skills requirements;
- A space in Europe for product trouble-shooting and repairs of damaged equipment. Formerly, such products had to be sent to the US;
- Warehousing and management of machines and parts to enhance supply chain and delivery times; and
- Access to OPEX’s European technical support staff.
“We have been expanding our facilities, personnel and infrastructure to meet the growing automation needs of our customers in Europe and around the world,” said Scott Maurer, OPEX President, International. “This new operation in Germany will give our customers the automation assistance they require in a location that is ideally located to maximize efficiency.”
OPEX automated warehouse management systems help customers maximize their warehouse space and manage peaks and demands without relying on additional labor. Scalable robots and automated warehouse systems optimize e-commerce fulfillment, micro-fulfillment and reverse logistics to handle returns with speed and reduced labor.
In addition, OPEX’s document and mail automation solutions offer seamless and secure mail sorting, document imaging and payment processing to improve business workflow and throughput while reducing or eliminating intensive document preparation.
About
OPEX Corporation provides Next Generation Automation, including warehouse, document and mail automation solutions, to customers around the globe. With headquarters in Moorestown, NJ―and facilities in Pennsauken, NJ; Plano, TX (Dallas metro); France; Germany; Switzerland; and the United Kingdom―OPEX has more than 1,450 employees committed to reimagining and delivering innovative, scalable, unique technology solutions to solve the business challenges of today.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20211109005371/en/
Contact information
Colleen Ciak
CCiak@opex.com
856.727.1100, ext. 5350
856.912.4952 Cell
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 21:00:00 EET | Press release
Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham, MSc, MD, FRCPC, dermatologist, SKiN Centre for Dermatology, Peterborough, Ontario, Canada, principal investigator for the Latitude PsO studies and presenting author. “These efficacy and safety results show it’s possible for a once-daily pill to deliver rapid, lasting skin clearance, highlighting the potential of zasoc
Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 21:00:00 EET | Press release
Incyte (Nasdaq:INCY) today announced 54-week data evaluating the safety and efficacy of povorcitinib (INCB54707), an oral small-molecule highly-selective JAK1 inhibitor, from the pivotal Phase 3 STOP-HS clinical trial program in adult patients (≥18 years) with moderate to severe hidradenitis suppurativa (HS). The late-breaking oral presentation of these data is taking place at the 2026 American Academy of Dermatology (AAD) Annual Meeting, being held March 27-31, 2026, in Denver (Session: S034 – Late-Breaking Research: Session 2. Saturday, March 28, 2026, 1:00-4:00 p.m. MT). “The 54-week results from the STOP-HS program deliver compelling, long-term evidence supporting the potential of povorcitinib for patients with moderate to severe HS,” said Pablo J. Cagnoni, M.D., President and Global Head of Research and Development, Incyte. “Across both studies, povorcitinib demonstrated substantial and durable improvements over time in key measures of treatment success and meaningful clinical ben
AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 17:00:00 EET | Press release
Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-breaking session at the 2026 American Academy of Dermatology (AAD) Annual Meeting. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260328320362/en/ Atopic dermatitis is the most common inflammatory skin disorder in children, yet treatment options in the moderate-to-severe pediatric setting are limited.5 The disease can have a significant impact on quality of life for both the patients and their loved ones, with persistent itch and recurrent skin lesions often disrupting sleep, school and relationships.5-8 “Atopic dermatitis can affect many aspects of children’s lives including schoolwork, emotional development
Angelalign Technology (6699.HK) Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 21:56:00 EET | Press release
Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti
Axway Positioned as a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment27.3.2026 19:46:00 EET | Press release
Axway, a 74Software company (Euronext: 74SW) and global leader in federated API management and enterprise integration, has been named a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment.1 Axway Amplify securely connects, orchestrates, and automates data integration. Organizations in financial services, manufacturing, healthcare, and other industries rely on Amplify to modernize integrations and confidently unlock data to deliver superior digital services faster. The report notes: “The platform benefits from Axway’s long-standing experience in B2B integration, secure file transfer, and legacy connectivity, providing differentiated capabilities for organizations that need to expose and control APIs around core systems that are not cloud-native.”1 This multi-pattern expertise in security, integration, and federated governance — built during the early phases of the API-driven digital transformation — becomes especially critical as enterprises seek to govern dat
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom